Please login to the form below

Not currently logged in
Email:
Password:

Claes Buxfeldt joins NDA

He becomes its new HTA director

AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.

During the past 18 years, Buxfeldt’s career has seen him work on a variety of disease areas, supporting more than 30 molecules/brands in global positions.

He has represented the payer voice in development programmes including the development of payer evidence strategies, pricing, market access strategy, economic models and clinical programme input.

Dr Werner Van den Eynde, vice president for the NDA advisory board, said: “We are very happy to welcome Claes on board as our new HTA director.

“Claes’ expertise will allow us to provide an even better service to our clients.”

Buxfeldt’s new role at NDA will see him drive and develop the group’s service offerings in the HTA area.

21st March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics